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Abstract
Human African trypanosomiasis is caused by the eukaryotic microbe Trypanosoma brucei. To discover new drugs against the
disease, one may use drugs in the clinic for other indications whose chemical scaffolds can be optimized via a medicinal
chemistry campaign to achieve greater potency against the trypanosome. Towards this goal, we tested inhibitors of human
EGFR and/or VEGFR as possible anti-trypanosome compounds. The 4-anilinoquinazolines canertinib and lapatinib, and the
pyrrolopyrimidine AEE788 killed bloodstream T. brucei in vitro with GI50 in the low micromolar range. Curiously, the genome
of T. brucei does not encode EGFR or VEGFR, indicating that the drugs recognize alternate proteins. To discover these novel
targets, a trypanosome lysate was adsorbed to an ATP-sepharose matrix and washed with a high salt solution followed by
nicotinamide adenine dinucleotide (NAD+). Proteins that remained bound to the column were eluted with drugs, and
identified by mass spectrometry/bioinformatics. Lapatinib bound to Tb927.4.5180 (termed T. brucei lapatinib-binding
protein kinase-1 (TbLBPK1)) while AEE788 bound Tb927.5.800 (TbLBPK2). When the NAD+ wash was omitted from the
protocol, AEE788, canertinib and lapatinib eluted TbLBPK1, TbLBPK2, and Tb927.3.1570 (TbLBPK3). In addition, both
canertinib and lapatinib eluted Tb10.60.3140 (TbLBPK4), whereas only canertinib desorbed Tb10.61.1880 (TbCBPK1).
Lapatinib binds to a unique conformation of protein kinases. To gain insight into the structural basis for lapatinib interaction
with TbLBPKs, we constructed three-dimensional models of lapatinibNTbLBPK complexes, which confirmed that TbLBPKs can
adopt lapatinib-compatible conformations. Further, lapatinib, AEE788, and canertinib were docked to TbLBPKs with
favorable scores. Our studies (a) present novel targets of kinase-directed drugs in the trypanosome, and (b) offer the 4-
anilinoquinazoline and pyrrolopyrimidines as scaffolds worthy of medicinal chemistry and structural biology campaigns to
develop them into anti-trypanosome drugs.
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Introduction
Human African trypanosomiasis (HAT) is caused by the
protozoan Trypanosoma brucei. New drugs for the treatment of
HAT are needed as the current ones have significant issues
relating to administration route, toxicity and/or drug resistance
[1,2]. To assist drug discovery efforts, we must find novel small
molecules that kill the parasite, and, in the long-term, also
understand the mechanisms of their action in the trypanosome.
Protein phosphorylation on Tyr residues, catalyzed by protein
Tyr kinases (PTKs) or dual-specificity protein kinases that act on
Tyr as well as Ser/Thr [3–6], is important for cell signaling
networks that control numerous processes [7]. PTKs in vertebrates
exist in two general forms; receptor tyrosine kinases (RTKs) and
non-receptor Tyr kinases (NRTKs). RTKs such as epidermal
growth factor receptor (EGFR) or vascular endothelial growth
factor receptor (VEGFR), are transmembrane proteins and are
activated upon binding of hormones to their extracellular
domains. NRTKs, e.g., Src-family protein kinases, are cytosolic,
and can be activated by RTKs or cytokine receptors.
Mechanistic studies of phosphotyrosine (pTyr) signaling in
human cells led to discovery of drugs (e.g., lapatinib, and imatinib)
that are incredibly well-tolerated [8–10]. Lapatinib (GW572016)
(GlaxoSmithKline) inhibits human EGFR/HER2 [11]. AEE788
(Novartis) inhibits EGFR and VEGFR [12,13], and canertinib
(CI-1033) (Pfizer) is a pan-inhibitor of EGFRs [14–16].
T. brucei has a divergent pTyr system, as compared to its human
host. Whereas Tyr-phosphorylated proteins are present [17,18],
trypanosomes lack RTKs [19,20]. Consequently, Tyr-phosphor-
ylation of proteins is projected to be performed by dual-specificity
enzymes that act on Ser/Thr as well as Tyr residues [19]. Further,
the trypanosome genome does not encode classic pTyr-binding
domains (e.g., SH2) [21]. The biological importance of Tyr-
phosphorylation in T. brucei is inferred from the effect of small
molecule Tyr kinase inhibitors; (i) genistein blocks trypanosome
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replication [22]; (ii) Tyrphostin A47 inhibits interferon-c induced
Tyr phosphorylation of proteins [23], and (iii) Tyrphostin A47
inhibits receptor mediated endocytosis by the parasite [24,25].
Due to the uniqueness of the Tyr-phosphorylation system in the
trypanosome it seems likely that a detailed understanding of pTyr
signaling (i.e., enzymes, substrates and pathways regulated) could
yield great insight into novel signal transduction pathways in a
deeply-diverged eukaryote, and lead to discovery of novel targets
for lead drug discovery.
Materials and Methods
Reagents
Immobilized c-aminophenyl-ATP-sepharose was purchased
from Jena Biosciences. NAD+, and ATP were purchased from
Sigma. Silver stain kit was obtained from Pierce. Lapatinib,
canertinib, and AEE788 were gifts from GlaxoSmithKline, Pfizer,
and Novartis, respectively.
Effects of Drugs on Trypanosome and HeLa Cell
Replication
Bloodstream form T. brucei brucei Lister 427 were seeded at a
density of 26103 cells/ml and cultured in HMI-9 medium [26] in
a 24 well plate. Two microliters of DMSO (control) or different
concentrations of drugs (as specified in the Figure legends) from
200X DMSO stocks were added to the cultures. Cells were
incubated at 37uC for 48 h, and counted with a haemocytometer.
HeLa cells were cultured in high glucose Dulbecco’s modified
Eagle’s medium (Cellgro) supplemented with 10% FBS (Hyclone),
100 U/ml penicillin (Cellgro), 100 mg/ml streptomycin (Cellgro)
[27]. Cells were cultured at 37uC with humidified 5% CO2. For
drug inhibition studies, cells were seeded in a 24 well plates at a
density of 16105 cells/ml. Drugs or DMSO were added in 2 ml up
to 25 mM final concentration. Cells were incubated at 37uC for
48 h and counted with a haemocytometer.
Drug Affinity Chromatography of Proteins
T. brucei were cultured axenically [26] to a density of 16106
cells/ml and harvested (26108 total cells). After washing with
10 ml of cold BBS/G (buffered saline plus glucose; 50 mM bicine,
150 mM NaCl, 5 mM KCl, 1% glucose, pH 7.4) containing
1 mM sodium vanadate, cells were lyzed on ice in 1 ml of cold
Buffer A (20 mM Tris-HCl pH 7.4, 60 mM MgCl2, 60 mM KCl,
1 mM DTT, 0.2% NP-40, 1 mM PMSF, 2 mg/mL aprotinin,
5 mg/ml leupeptin, 37 mg/ml TLCK, 2 mM FMKO24, and
1 mM sodium vanadate). The cell lysate was incubated on ice
for 20 minutes and centrifuged at 15,0006g for 10 min at 4uC.
The supernatant was incubated for 18 h at 4uC with 50 ml (settled
bed volume) of ATP-sepharose (Sepharose 4B was used as control
in a separate experiment.) The resin was washed with 500 ml each
of the following (i) buffer A; (ii) buffer A containing 1 M KCl, and
finally (iii) buffer A. When specified, the resin was eluted twice with
100 mM NAD+ (100 mM in buffer A).
Several concentrations of drugs (i.e., 1 mM, 10 mM, and
100 mM) were used in trial experiments to elute proteins from
the ATP-affinity column. For (subsequent) mass spectrometry
analysis it is important that the bands detected by silver staining of
protein be sufficiently dark. After analysis of the proteins eluted in
several independent trial studies, we determined that 100 mM
concentration was optimal for elution of proteins bound by
lapatinib, AEE788 and canertinib: The drug concentration
needed varies for each scaffold. For each drug, proteins bound
to the affinity column were eluted twice (from different matrices)
with 100 ml of lapatinib (100 mM) or AEE788 (100 mM) or
canertinib (100 mM) (Drugs are diluted to their final concentra-
tions in buffer A from DMSO stocks at 10 mM concentration). A
control elution was performed with buffer A containing 1%
DMSO, because the final concentration of that solvent in the drug
mixtures was 1%, and eluted proteins identified by mass
spectrometry. Eluted polypeptides were precipitated with trichlor-
oacetic acid and pelleted (15,0006g for 10 min). The supernatant
was aspirated, the precipitate was suspended in 26 SDS-PAGE
sample buffer (10 ml), and the pH adjusted by adding 5–7 ml of
30% NH4OH. Proteins were separated by SDS-PAGE (12%), and
polypeptide bands detected by staining with silver. Each lane of gel
was cut into four pieces each of which was minced with a sterile
blade in preparation for trypsinization (see below).
In-gel Trypsin Digestion and Mass Spectrometry
Polyacrylamide gel pieces were destained with a kit (Invitrogen),
and dehydrated with acetonitrile. Proteins were digested overnight
with trypsin (5 ng/ml, Promega) in ammonium bicarbonate
(50 mM) at 37uC. Peptides were extracted with formic acid (5%
v/v in water) for 30 min, and then with acetonitrile. Extracts were
pooled, dried in a SpeedVac, and peptides were purified with
ZipTipTM C18 chromatography (Millipore Corporation).
Figure 1. Chemical structure of lapatinib, AEE788, and
canertinib.
doi:10.1371/journal.pone.0056150.g001
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In the work reported here, we show that the 4-anilinoquina-
zolines lapatinib and canertinib kill bloodstream T. brucei. Since
the trypanosome genome does not encode orthologs of EGFR/
HER2, we searched for and identified novel trypanosome targets
of the drugs, using an affinity chromatography protocol that
involved protein elution with drugs: Proteins were identified with
mass spectrometry and bioinformatics. This protocol which is
easily adaptable for discovering targets of kinase inhibitors in
other cells, led to identification five novel binding-proteins of
lapatinib, AEE788, and canertinib in T. brucei. The four putative
targets of lapatinib were evaluated theoretically for their ability to
bind the drug using homology modeling and molecular docking.
Results from these studies support conclusions drawn from our
ligand-affinity chromatography data.
LC-MS/MS analysis was performed with a LTQ mass
spectrometer (Thermo Scientific). The LC system was configured
in a vented format consisting of a fused-silica nanospray needle
packed in-house with Magic C18 AQ 100 A˚ reverse-phase media
(Michrom Bioresources Inc.), and a trap containing Magic C18
AQ 200 A˚ [30]. Peptide samples were loaded onto the column and
separated using a two-mobile-phase system consisting of 0.1%
formic acid in water (A) and 0.1% acetic acid in acetonitrile (B).
The mass spectrometer was operated in a data-dependent MS/
MS mode over the m/z range of 400–1800. For each cycle, the five
most abundant ions from the scan were selected for MS/MS
analysis using 35% normalized collision energy. Selected ions were
dynamically excluded for 45 seconds. Raw MS/MS data were
submitted to the Computational Proteomics Analysis System
(CPAS), a web-based system built on the LabKey Server v11.2
that utilizes Trans-Proteomic Pipeline v4.3 [28,29], and searched
using X! Tandem engine (2009.10.01.1) against T.brucei protein
database v. 4.0 (ftp://ftp.sanger.ac.uk/pub/databases/T.
brucei_sequences/T.brucei_genome_v4/), which included addi-
tional common contaminants such as human keratin. The
following modifications were considered: loss of water or ammonia
from terminal glutamic acid or glutamine respectively, and
oxidation of methionine. The mass tolerances were set 62 Da
and 60.5 Da for precursor and fragment ions respectively. The
enzyme was set to Trypsin, and up to 2 missed cleavages were
permitted. The search output files were analyzed and validated by
ProteinProphet [30,31]. Peptides matched with an error rate
,0.05 were accepted, and corresponding proteins identified with
two or more peptides are reported. Experiments were repeated
thrice; proteins are reported only if they were detected in at least
two separate experiments (Table 1). Properties of peptides used to
identify protein kinases are presented in Table S1.
Structure-directed Sequence Alignment of Lapatinib-
binding Pockets
All four trypanosome kinases have medium to high homology
templates in PDB (Table 2). The closest homology templates for
TbLBPK1 and TbLBPK3 in the PDB are a putative calcium-
dependent protein kinase 1 from Cryptosporidium parvum
(CpCDPK1, Uniprot ID A3FQ16, 34% sequence identity to
TbLBPK1 in the kinase domain) and a putative calcium-
dependent protein kinase 3 from Toxoplasma gondii (TgCDPK3,
Uniprot ID Q3HNM6, 30% sequence identity to TbLBPK3 in the
kinase domain). Despite belonging to CaMK family of Ser/Thr
kinases, both of these templates are crystallized in lapatinib-
compatible backbone conformations (PDB codes 2wei and 3hzt,
respectively). In the case of TbLBPK2 and TbLBPK4, the closest
homology templates human casein kinase Id (Uniprot ID
KC1D_HUMAN) and a putative glycogen synthase kinase from
Leishmania major (Uniprot ID Q4QE15), respectively, are crystal-
lized in an active-like, and therefore lapatinib-incompatible
conformation. Thus, the closest template models of TbLBPK1
and TbLBPK3 were capable of favorably docking lapatinib while
the closest template for TbLBPK2 and TbLBPK4 could not. We
hasten to add that the lapatinib-conformation is dynamic; it is an
alternate to the enzyme active-conformation. Therefore, its
absence from an x-ray structure does not preclude its existence;
in some instances presence of the drug might stabilize lapatinib-
compatible conformations in select protein kinases.
Given this background (above), we enhanced modeling based on
closest homology templates with more distant modeling protocols using
structures of human EGFR in complex with lapatinib (PDB 1xkkA
[32]) as templates, since our affinity chromatography studies identified
TbLBPKs as lapatinib-binding polypeptides. These structures provid-
Table 1. Protein kinases eluted with drugs after 1 M KCl wash
of the affinity column.
Protein Peptides Peptide Sequence Residue no.
Tb927.4.5180
(TbLBPK1)
6 K.QQQQDLNHEK.K 280–291
R.RDEVEELK.K 220–229
K.AFDLQEAR.Y 336–345
R.RPFAEGESQQQIWQNK.L 537–554
R.QLTM’QLEELSVR.R 208–221
K.Q‘ATLPSYGLVNDTAVFR.K 92–110
Tb927.5.800
(TbLBPK2)
4 K.TRHPQLAFEAR.F 45–57
R.GTNIQTGDPVAIK.L 27–41
K.TTLM’LAEQM’IAR.I 108–121
R.GSLPWQGLK.A 213–223
Tb927.3.1570
(TbLBPK3)
2 R.RPLSICDSPSLEAK.F 118–133
K.ASLFTDILPTAATLPK.R 497–514
Tb10.61.3140
(TbLBPK4)
2 R.VAGQGTFGTVQLAR.D 24–39
K.Q‘PLPAEVYDLCGK.I 276–290
Canertinib
Protein Peptides Peptide Sequence Residue No.
Tb927.4.5180
(TbLBPK1)
8 K.QQQQDLNHEK.K 280–291
R.RDEVEELKK.T 220–230
R.EVWVEGNK.M 198–207
K.AFDLQEAR.Y 336–345
R.RPFAEGESQQQIWQNK.L 537–554
R.VNDEDASAFVAVPALGHNGR.Y 299–320
K.QATLPSYGLVNDTAVFR.K 92–110
R.LIIM’QVVSALR.Y 426–438
Tb927.5.800
(TbLBPK2)
7 R.THQHIPYK.E 165–174
K.RIHDTLQEGR.A 298–309
K.TRHPQLAFEAR.F 45–57
R.GTNIQTGDPVAIK.L 27–41
R.YCSINTHIGIEQSR.R 183–198
K.TTLM’LAEQM’IAR.I 110–121
R.GSLPWQGLK.A 213–223
Tb927.3.1570
(TbLBPK3)
3 R.LAEQGLK.K 136–144
R.GDNTSGDWGYYK.R 198–211
K.ASLFTDILPTAATLPK.R 497–514
Tb10.61.3140
(TbLBPK4)
2 K.NYFYTVGGEGR.R 80–92
R.VAGQGTFGTVQLAR.D 24–39
Tb10.61.1880
(TbCBPK1)
2 K.LADFDQAK.V 154–163
K.GDNLLISM’DTGIAK.L 140–155
AEE788
Lapatinib-Binding Proteins from a Trypanosome
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Lapatinib
ed a variety of suitable backbone conformations of the kinase domains
for the modeling studies. Sequence identity between EGFR and
TbLBPKs is between 18% and 22%, which is below the 40% cutoff for
reliable homology modeling [33–35]. Consequently, sequence align-
ment methods failed to find the correct residue correspondence in
several regions of the kinase domain. We resolved the alignment
ambiguities by constructing structural alignments of EGFR to the
closest homology templates of TbLBPKs in PDB (Table 1) followed by
propagation of the obtained residue correspondence onto the target
sequences via a sequence-based alignment. From these, lapatinib-
binding was discerned.
Homology Modeling of TbLBPK Structures
The structures of TbLBPK1-4 and TbCBPK1 were built using the
homology modeling platform of the Internal Coordinate Mechanics
(ICM) software [36–38]. Initially, well-aligned regions of the target
kinase were threaded through the backbone coordinates of the
template structure. Loops, insertions and deletions were searched
against a large database of PDB fragments for similar sequence and
termini topology; well-scoring fragments were incorporated into the
nascent model and minimized in its context. Template hydrogen bonds
were converted into distance restraints; the model side-chains were
thoroughly sampled to find the global minimum of the energy function
that included soft van der Waals, electrostatic, hydrogen bonding,
torsional strain, and distance restraint terms. To resolve the remaining
steric conflicts, the model was subjected to gradient minimization with
both side-chain and backbone variables relaxed. The final models were
evaluated using two methods: first, ICM Protein Health evaluation
confirmed the absence of torsional or steric inaccuracies; second,
PROCHECK [39] evaluation placed at least 80% of the residues in
the most favorable regions on the Ramachandran plot with at least
97% being in the allowed regions. Visual inspection of the remaining
(unfavorable) residues confirmed that they located in extended loops
distant from the lapatinib binding site and were therefore not influential
in the docking studies.
Ligand Docking and Scoring
ICM ligand docking is based on biased probability Monte Carlo
optimization of the ligand internal coordinates in the set of grid
potential maps that represent the protein binding pocket. A diverse set
of ligand conformers was first generated from 2D coordinates by 2D to
3D conversion and thorough sampling in vacuo. The conformers were
placed into the binding pocket in four principal orientations and used
as starting points for Monte Carlo optimization. The optimized energy
function included the ligand internal strain and a weighted sum of the
grid map values in ligand atom centers. The top-scoring ligand poses
were merged with the kinase models to obtain full-atom models of the
complexes which were further evaluated with full-atom ICM ligand
binding score [40]. The score was calculated by:
Sbind~EintzTDSTorzEvwza1Eelza2Ehbza3Ehpza4Esf
where Evw, Eel, Ehb, Ehp, and Esf are Van der Waals, electrostatic,
hydrogen bonding, non-polar and polar atom solvation energy
differences between bound and unbound states, Eint is the ligand
internal strain, DSTor is its conformational entropy loss upon
binding, T = 300 K, and ai are ligand- and protein-independent
Table 1. Cont.
AEE788
Protein Peptides Peptide Sequence Residue no.
Tb927.4.5180
(TbLBPK1)
8 K.Q‘QQQDLNHEK.K 280–291
R.DAQIDELR.E 115–124
K.AFDLQEAR.Y 336–345
R.RPFAEGESQQQIWQNK.L 537–554
R.QLTM’QLEELSVR.R 208–221
R.VNDEDASAFVAVPALGHNGR.Y 299–320
K.QATLPSYGLVNDTAVFR.K 92–110
R.LIIM’QVVSALR.Y 426–438
Tb927.5.800
(TbLBPK2)
4 R.IEFVHSK.S 120–128
K.TRHPQLAFEAR.F 45–57
R.GTNIQTGDPVAIK.L 27–41
R.GSLPWQGLK.A 213–223
Tb927.3.1570
(TbLBPK3)
5 R.RGGGPETSPPR.G 187–199
R.RPLSICDSPSLEAK.F 118–133
R.LSNGEVVLEVENR.S 439–453
R.DLKPQNLLLTGR.S 348–361
K.ASLFTDILPTAATLPK.R 497–514
Proteins presented were detected at least twice in three independent affinity
chromatography/mass spectrometry analyses.
doi:10.1371/journal.pone.0056150.t001
Table 2. TbLBPKs1-4 and their structural homologs in PDB.
Protein Kinase System ID UniProt ID Kinase Domain Closest PDB homologs
SwissProt ID
Sequence Identity to
Target (%)
TbLBPK1 Tb927.4.5180 Q584I8 320:601 SNF1_YEAST, A3FQ16_CRYPV 31, 34
TbLBPK2 Tb927.5.800 Q57W25 11:282 KC1D_HUMAN 69
TbLBPK3 Tb927.3.1570 Q57XZ0 213:488 MARK2_HUMAN
B6KR85_TOXGO
32, 30
TbLBPK4 Tb10.61.3140 Q388M1 (GSK3c) 20:310 Q4QE15_LEIMA
GSK3B_HUMAN
69, 54
TbCBPK1 Tb10.61.1880 Q388C6 16:284 M3K5_HUMAN, PAK1_HUMAN 37.5, 37.3
doi:10.1371/journal.pone.0056150.t002
Lapatinib-Binding Proteins from a Trypanosome
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e56150
constants that have been previously optimized on a diverse
screening benchmark.
Results
Lapatinib, Canertinib and AEE788 Inhibit Replication of
T. brucei at Low Micromolar Concentrations
In the African trypanosome, endocytosis of transferrin, which is
necessary for replication [41], is inhibited by Tyrphostin A47, a
pan-Tyr kinase inhibitor that also kills the parasite [24]. This data
suggests that chemical scaffolds of drugs that inhibit protein Tyr
kinases have potential to be ‘‘re-purposed’’ for anti-trypanosome
lead drug discovery.
Lapatinib, canertinib and AEE788 (Fig. 1) are Tyr kinase
inhibitors that have passed phase I clinical trials, at least, for use in
humans [42–45]. In addition, the chemistry for synthesis of these
drugs is well established and streamlined for optimization
[11,46,47]. To evaluate effects of these drugs on T. brucei,
axenically cultured bloodstream cells were exposed to different
amounts of the compounds, and checked for viability. Lapatinib
killed T. brucei (GI50 = 1.5 mM(Fig. 2A)). Similarly, canertinib and
AEE788 killed the trypanosome with an GI50’s of 2 mM, and
3 mM, respectively (data not presented). Ability of lapatinib to
interfere with pro-survival pathways (i.e., kill within the half-time of
cell replication) in T. brucei was tested directly. When cells (106/ml)
were incubated with the drug the survival half-life was 3 h
(Fig. 2C), which is shorter than the cell division time of 6–8 h.
Toxicity of lapatinib against T. brucei was compared to its effect
on a human HeLa cell line. At 5 mM or 10 mM all trypanosomes
were killed but the human cells survived (Fig. 2B), presumably
because growth of HeLa is not dependent on a hyperactive
EGFR/HER2 [9,12]. Selectivity of lapatinib against the trypano-
some is similar to that observed for the drug when tumor cells are
compared to untransformed (non-sensitive) human cells [11,48].
Lapatinib, Canertinib and AEE788 Bind Five Trypanosome
Protein Kinases
The respectable whole cell potency (i.e., in a phenotypic screen)
of lapatinib, canertinib and AEE788 against T. brucei (Fig. 2) could
not be explained by inhibition of EGFR and/or VEGFR kinases,
because the trypanosome genome does not encode classic receptor
Tyr kinases [49]. Therefore, we postulated that the drugs had
alternate protein targets in the trypanosome.
To identify the trypanosome targets of the drugs we used them
as chemical tools. In our approach, a cell lysate from T. brucei was
adsorbed to an ATP-sepharose column. After extensive washing of
the ATP-affinity column with buffers containing high salt (i.e., 1 M
KCl) and/or NAD+ (100 mM), the drugs (100 mM) were used to
elute proteins remaining on the column. Proteins eluted were
identified by mass spectrometry and bioinformatic analysis
[29,50,51]. The profile of proteins eluted with drugs after the
high salt wash is shown in Fig. 3B–D, and protein kinases
identified are listed in Table 1. In preliminary studies, the profile
of eluted proteins was very similar for the 1 or 10 or 100 mM drug
concentrations. The higher concentration of drug eluted more
proteins from the affinity column, judging from the intensity of the
silver-stained bands and the number proteins identified by mass
spectrometry (see Table S2 and Table S3); it was used for our
studies.
Only five protein kinases, out of a possible 186 in the
trypanosome genome [19,52] bound the three drugs.
Tb927.3.1570, Tb927.4.1580 and Tb927.5.800 were eluted with
AEE788, canertinib and lapatinib (Table 1). Tb10.60.3140 was
eluted by both canertinib and lapatinib, whereas Tb10.61.1880
Inclusion of NAD+ in Washes of the Affinity Column Alters
Profile of Protein Kinases Eluted by Drugs
Cells contain purine cofactors and nucleotides, including NAD+,
whose structure overlaps significantly that of ATP, which is a
substrate of protein kinases. Recognizing the possibility that
Figure 2. Lapatinib, AEE788 and canertinib kill bloodstream T.
brucei. Bloodstream form T. brucei (initial cell density of 26103 cells/ml)
were cultured in 24-well plates for 48 h with either DMSO (control) or
different concentrations of drug. Cells were counted with a hemocy-
tometer and the graphs plotted. Data are mean 6 standard deviation
obtained from two independent experiments performed in duplicate. (A).
Effect of lapatinib on growth of T. brucei. (B). Comparison of growth
inhibitory effect of lapatinib on T. brucei to HeLa cells. HeLa and T. brucei
cells were cultured for 48 h with variable concentrations of lapatinib.
Relative cell density represents the live cells expressed as percentages of
the control (i.e., DMSO-treated) experiment. (C) Trypanosome kill assay.
Time-course of trypanocidal effect of lapatinib. Trypanosomes (106 cells/
ml) were treated with DMSO (solvent) or lapatinib (10 mM) for 8 h: viable
cells were counted every hour, and plotted for each time point.
doi:10.1371/journal.pone.0056150.g002
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was only eluted by canertinib. Three lapatinib-binding protein
kinases (TbLBPKs) have been studied earlier; TbLBPK1 (termed a
Tousled-like kinase) [53,54], TbLBPK-2 (TbCK1.2 [55]) and
TbLBPK4 (TbGSK3β [56]). Non-kinase ATP-binding proteins
detected in our dataset are available in Table S2. We focused
primarily on protein kinases because lapatinib binds that class of
enzymes in human cells [57].
protein kinases may bind weakly to NAD+, we explored a second
strategy for our chemical proteomics study. Here, after washing
the affinity column with the high salt buffer, we eluted the matrix
with NAD+ (100 mM) before desorbing the residual proteins with
drugs (see Fig. 3). Protein kinases in drug eluates are presented in
Table 3.
After the NAD+ wash, only two protein kinases were eluted
from the affinity column. Tb927.4.5180 was eluted with
lapatinib, and Tb927.5.800 was found in the AEE788 eluate.
Canertinib failed to elute any protein kinase with this revised
protocol. One explanation for these data, compared to proteins
protein kinases, and found Tb927.5.800, Tb10.70.2070,
Tb10.61.1880, and Tb10.61.3140. We conclude that NAD+
can elute select trypanosome protein kinases from an ATP-
affinity column, and alter the profile of proteins eluted by drugs
from the ATP-affinity matrix.
Binding of Lapatinib or NAD+ to TbLBPKs is Affirmed by
Molecular Modeling
The affinity chromatography data indicates that lapatinib, as a
model inhibitor, binds to 4 protein kinases (Table 1). Yet an NAD+
wash of the column left Tb427.4.5180 (TbLBPK1) as the sole
kinase eluted by the drug (Table 3). A similar situation is observed
with AEE788 that binds three TbLBPKs initially but after the
NAD+ elution only desorbs TbLBPK2 (compare Table 1 and
Table 3).
There are two possible explanations for these observations. One
possibility is that NAD+ binds to an ATP-binding ‘‘passenger
protein’’ that associates with some TbLBPKs that do not directly
bind the affinity column. As a result, removal of the passenger
elutes proteins from the affinity column leaving only those that
bind tightest to ATP. At this point only drugs with significant
affinity for a TbLBPK can elute the protein from the affinity
matrix. Using computational approaches, we have evaluated,
ahead of biochemical analysis, whether either any of these ideas
have merit, by testing whether TbLBPKs bind lapatinib or NAD+
or ATP.
Lapatinib binds and/or stabilizes a specific inactive conforma-
tion of the kinase domain in its human targets [58–60]; this
conformation is characterized by (i) broken conserved Lys-Glu salt
bridge, (ii) outward movement of the aC helix, and (iii) flipped
conserved Phe at the base of the activation loop (DFG motif).
Because of the inherent plasticity of the kinase domain, this
conformation can also be spontaneously adopted or induced in
many other kinases: according to our estimates, up to 45% of
kinases in the PDB are found at least once in a lapatinib-
compatible conformation. For the study of the structural
determinants of lapatinib interaction with TbLBPKs 1–4, it is
important that these target kinases are modeled in the lapatinib-
compatible conformation. The closest homology templates for
TbLBPK1 and 3 (but not TbLBPK2 or 4) have lapatinib-
compatible X-ray structures (Fig. 4). As a trade-off between
conformational relevance of the homology modeling template and
the level of its sequence homology to the target(s), we chose to
model TbLBPKs from human EGFR in several conformational
variants [59].
Figure 3. Drug elution of T. brucei protein kinases using an ATP-affinity resin. Proteins in total cell lysate from T. brucei were bound on ATP
resin. Sepharose 4B resin was used as control. Unbound proteins (Flow through) were recovered and resin was washed sequentially with buffer A and
buffer A containing 1 M KCl (Panel A). Bound proteins were eluted with lapatinib (100 mM), or AEE788 (100 mM) or canertinib (100 mM) (Panel B, C and
D, respectively). Proteins were visualized by silver staining. Matrix label, A is ATP-sepharose, and S is Sepharose 4B.
doi:10.1371/journal.pone.0056150.g003
Table 3. Proteins eluted with lapatinib, or AEE788 or canertinib after 1 M KCl and 100 mM NAD+ washes of the affinity
chromatography column.
Protein Description Lapatinib AEE788 Canertinib
Total peptides Total peptides Total peptides
Tb927.4.5180 Protein Kinase putative 6 0 0
Tb927.5.800 Protein Kinase 0 3 0
Proteins listed are detected at least twice in three separate affinity chromatography/mass spectrometry studies.
doi:10.1371/journal.pone.0056150.t003
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eluted without the NAD+ wash (compare Table 1 and Table 3),
is that some protein kinases were eluted by NAD+. We
evaluated this hypothesis by analyzing the NAD+ eluate for
is that TbLBPKs bind both ATP and NAD+ due to structural
similarities between the two small molecules. In this view, NAD+
NAD+protein with            also elutes those TbLBPKs leaving only those
thatdid not bind the passenger protein. An alternative explanation
The models constructed as described in Materials and Methods
helped to elucidate possible structural basis of TbLBPK interac-
tion with lapatinib and AEE788 and to identify amino residues
that shape the drug-binding pocket (Fig. 5). This computational
model confirmed that TbLBPKs can adopt the lapatinib-
compatible backbone conformation, and that in all four cases,
pocket residues are positioned favorably for lapatinib binding
(Fig. 5A).
Docking scores for different kinaseNdrug complexes were
consistent with the affinity chromatography data (Table 1 and
Table 3): lapatinib, AEE788, and canertinib scored most favorably
in the models of TbLBPK1, TbLBPK2, and TbCBPK1,
respectively (Fig. 6A). The best poses for the drug binding to the
protein kinases are depicted in Fig. 6B. In comparing the
chromatography data with the models we found than an
arbitrarily chosen ICM score cutoff of 242 separates drug/kinases
complexes that are resistant to NAD+ elution from the ATP-
affinity column. For canertinib, the results obtained make for
interesting discussion: TbCBPK1 docks best to canertinib (among
the three drugs tested). However the ICM score was less than 42
for all three drugs, suggesting that TbCBPK1 will not be eluted by
any drug from the affinity column after an NAD+ wash (Fig. 6A).
These data suggest that the models could have predictive value: a
ligandNTbLBPK complex that receives a score 241 or less is not
likely to be eluted from the ATP-affinity column after an NAD+
wash (Table 3 and Table 4).
How could one explain the decreased docking scores, as
compared to TbLBPK1, for TbLBPK2 and TbLBPK4? Here the
Figure 4. Closest homology templates for TbLBPK1 (magenta) and
TbLBPK3 (navy) are crystallographically observed in a conforma-
tion similar to that of lapatinib-bound human EGFR (white).
doi:10.1371/journal.pone.0056150.g004
Figure 5. Homology modeling of T. brucei lapatinib-binding kinases using structures of human EGFR as templates. (A) Alignment of
lapatinib binding site residues. (B) Binding site structures colored according to the alignment. (C) Models of TbLBPK’s1-4 complexed with lapatinib.
doi:10.1371/journal.pone.0056150.g005
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decrease in predicted binding affinity of lapatinib may be
explained by a missing residue in the hinge region (as compared
to human EGFR), which leads to non-optimal orientation of the
backbone amide groups. In the case of TbLBPK3, the likely
reason for a docking score decrease is a modified environment for
the fluorophenyl moiety of the drug, which, for example, includes
a non-conservative substitution of Leu in EGFR for Tyr in
TbLBPK3 (b4 strand of the kinase) (Fig. 5).
We also tested whether TbLBPKs bind NAD+ as postulated
earlier. For this objective, we constructed models of TbLBPKs in
the ATP-compatible conformation and docked ATP or NAD+ into
the models. Due to high structural similarity between ATP and
NAD+, both molecules fit well in the binding pockets and make
similar hydrogen bonds with the hinge region and with the
conserved Lys in the b3 strand of the kinase. However, entropic
and solvation electrostatics penalties for the larger and more
flexible NAD+ molecule led to better binding scores for ATP
(Fig. 7). These results indicate that high concentrations of NAD+
are likely to compete with ATP for binding to TbLBPK and may
wash some TbLBPKs off the ATP-affinity column. This prediction
is confirmed by detection of Tb927.10.5140, Tb927.5.800
(TbLBPK2), and Tb10.61.1880 in the NAD+ eluate from the
Figure 6. Best models of TbLBPKNdrug complexes are consistent with affinity chromatography elution data. (A) Predicted ICM binding
scores of lapatinib (red), AEE788 (green) and canertinib (magenta) in the binding pockets of the protein kinases. The dotted line represents a
hypothetical cutoff for kinase elution by drug after an NAD+ wash of the affinity column. (B) Predicted binding poses for lapatinib (red), AEE788
(green) and canertinib (magenta) to their highest affinity protein kinases; TbLBPK1, TbLBPK2, and TbCBPK1, respectively. Kinase hinge region is shown
in ribbon, ligand atom placement surface is represented by a wire mesh and colored according to its binding properties.
doi:10.1371/journal.pone.0056150.g006
Table 4. An NAD+ wash of affinity columns alters ligand
selection of target proteins.
Protein Lapatinib AEE788 Canertinib
KCL KCl/NAD+ KCL KCl/NAD+ KCL KCl/NAD+
Tb927.3.1570 + 2 + 2 + 2
Tb927.4.5180 + + + 2 + 2
Tb927.5.800 + 2 + + + 2
Tb10.61.1880 2 2 2 2 + 2
Tb10.61.3140 + 2 2 2 + 2
doi:10.1371/journal.pone.0056150.t004
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ATP-affinity column (not presented). Interestingly, one protein
kinase eluted by NAD+ i.e., Tb927.10.5140 was not eluted by any
of the drugs used in this study.
Discussion
New Chemical Entities for Anti-Trypanosome for Hit-to-
Lead Studies
Current anti-trypanosome chemotherapies are difficult to
deliver safely and some can be very toxic [1]. For example, in
late stage human African trypanosomiasis (HAT) when the
parasite has entered the central nervous system, the arsenical
drug melarsoprol is the frontline treatment despite its toxicity (5%
of patients die from side effects). Consequently, a pressing need
exists for new therapeutics with oral bioavailability and good safety
profile.
We discovered that endocytosis of transferrin by bloodstream T.
brucei is inhibited by Tyrphostin A47 [24,25], a pan-inhibitor of
protein Tyr kinases that also kills the parasite (Subramanya and
Mensa-Wilmot, unpublished). We inferred from these data that
inhibitors of T. brucei protein Tyr kinases or dual-specificity protein
kinases (trypanosomes lack classic Tyr kinases (e.g., EGFR)) might
be valuable as ‘‘hits’’ for anti-trypanosome lead drug discovery.
After performing a ‘‘focused screen’’ of investigational or approved
Tyr kinase drugs, we settled on the 4-anilinoquinazolines
carnetinib (CI-1033) [14,46,61] and lapatinib (GW572016)
[42,58], and the pyrrolopyrimidine AEE788 [12,62] (Fig. 1) as
possible ‘‘hits’’ for anti-trypanosome lead discovery. Canertinib,
lapatinib, and AEE788 killed bloodstream T. brucei, with GI50 of
3 mM or less (Fig. 2).
The biological importance of three TbLBPKs has been
medicinal chemistry optimization [63–65] as anti-trypanosomal
agents. That work is in progress.
A General Method for Discovering Targets of Kinase
Inhibitor Drugs
Lapatinib kills bloodstream T. brucei with a GI50 in the low
micromolar range (Fig. 2). To advance studies aimed at optimizing
anti-trypanosome properties of lapatinib, it is important to identify
the protein kinases that recognize the drug. This task is made
challenging by the absence of EGFR/HER2 family of kinases in
T. brucei [19,52]. Chemical proteomics [66] involving drug affinity
chromatography seemed a reasonable path to discover the
trypanosome targets for lapatinib. Nevertheless, we opted to
develop a more versatile protocol that would not require the use of
specialized matrices containing covalently attached kinase inhib-
itors (e.g., kinobeads) [66,67].
Since all protein kinases can bind to ATP, one could use the tri-
nucleotide as a universal ligand for that class of enzymes (as well as
other ATP-binding proteins). Therefore we used an ATP-affinity
column, instead of covalently attaching the drugs directly to a
matrix. After that we bound a lysate of total cellular proteins to the
affinity column, we washed it stringently to disrupt non-specific
protein-matrix interactions, and then eluted with drugs (e.g.,
lapatinib or canertinib or AEE788). Proteins eluted by the drugs
were identified with mass spectrometry and bioinformatic
approaches (see Materials and Methods) (see Table 1). Our approach
can be used to discover cellular targets of drugs that interfere with
ATPNprotein interactions/metabolism. Indeed we have used the
protocol to discover trypanosome protein targets of drugs other
than those reported here (R. Behera and K. Mensa-Wilmot, in
preparation.). A related technique was published while this
manuscript was being written [68].
It is worth mentioning that the protocol devised for this study
parallels the situation that a drug encounters intracellularly where
ATP is present at millimolar levels. Our protocol replicates this
scenario by adding a cell lysate to an ATP affinity column first,
before introducing a drug to elute the target protein. ATP
Figure 7. Docking of NAD+ and ATP to homology models of TbLBPKs and TbCBPK1.
doi:10.1371/journal.pone.0056150.g007
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characterized in RNA interference studies; TbLBPK1 (previously
named Tousled-like kinase) [53,54], TbLBPK2 (TbCK1.2 [55])
and TbLBPK4 (TbGSK3β [56]) are essential for viability of
bloodstream T. brucei. Our discovery that these essential enzymes
bind 4-anilinoquinazoline drugs that kill the parasite suggests that
this class of small molecules is a valuable starting point for
concentration on the affinity column is estimated to be about
1–10 mM [69]. To elute specific proteins, one can use as low as
1 mM of drug and titrate the concentration up as desired until one
detects clear bands in silver-stained polyacrylamide gels (see Fig. 2
for example). The latter condition is important for successful
identification of proteins by mass spectrometry.
Four Trypanosome Proteins are Likely to Adopt a
Lapatinib-Compatible Backbone Conformation
Lapatinib is one of the most selective among 38 kinase inhibitors
tested against 317 human enzymes [57]. In addition to the Tyr
kinases EGFR/HER2, the drug binds with appreciable affinity to
three other protein kinases, namely STK10/LOK, RIPK2, and
STK2/SLK [70–72]. This high selectivity of lapatinib is partially
due to a specific conformation of the kinase domain bound by the
drug [32]; it is characterized by (i) a broken conserved Lys-Glu salt
bridge, (ii) a displaced aC helix, and (iii) a flipped conserved Phe at
the base of the ‘‘activation loop’’ (i.e., DFG motif) [64,73,74].
Up to 45% of kinases in the PDB, according to our estimates,
can adopt a lapatinib-compatible backbone conformation (unpub-
lished). Many structures of proteins with high sequence homology
to TbLBPKs (Table 2) have features of the lapatinib-bound state,
e.g. Cryptosporidium parvum calcium-dependent protein kinase 1 (with
sequence similarity to TbLBPK1) and Toxoplasma gondii calcium-
dependent protein kinase 3 (which has protein sequence similarity
to TbLBPK3). Modeling of TbLBPKs from a lapatinib-compat-
ible EGFR template (PDB 1xkk) produced structures that are free
of steric conflicts or energetically strained regions (Fig. 4). These
modeling data support conclusions that trypanosome lapatinib-
binding proteins can adopt a lapatinib-compatible backbone as
one of the equilibrium conformations for their kinase domains
(Fig. 5).
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